Introduction to Encapsulating Hydrophilic vs Hydrophobic APIs in PLGA The development of clinically successful long-acting parenteral formulations depends on aligning […]
Encapsulating Hydrophilic vs Hydrophobic APIs in PLGA: Key Formulation Differences Read More »
Assessing the chemical safety of human drug products requires a thorough understanding of potential mutagenic and carcinogenic impurities that fall
Navigating Clinical Translation of CNS Small Molecules Under FDA Fast Track The clinical translation of central nervous system (CNS)-active small
Introduction: In peptide drug development, the quality of your analytical data is only as good as the reference standard anchoring
Identifying and addressing the root causes of failed Extractables and Leachables (E&L) studies has become a critical regulatory requirement for
Introduction Burst release in PLGA formulations is one of the most clinically consequential — and analytically challenging — phenomena in
Understanding Burst Release in PLGA Formulations — Causes, Consequences, and Mitigation Read More »
Introduction: When a nitrosamine exceeds the acceptable intake limit in a drug product or active pharmaceutical ingredient (API), it triggers
Introduction: Patient safety begins long before a drug product reaches the clinic — it begins with the container that holds
Extractables and Leachables (E&L) Testing for Container Closure Integrity Programs Read More »
Introduction: Carmustine PLGA characterization sits at the intersection of polymer science, oncology pharmacology, and regulatory compliance — making it one
Introduction: Aripiprazole lauroxil (Aristada®) is a PLGA-based long-acting injectable antipsychotic that differs fundamentally from other LAI microsphere products. As discussed
